Global Health & Biotech Archives | Page 6 of 285 | Be Korea-savvy

Archive by category Global Health & Biotech

New Global Coalition Launches to Address the Hidden Threat of RSV in Adults

New Global Coalition Launches to Address the Hidden Threat of RSV in Adults

VIENNA, Austria, Oct. 26, 2025 (Korea Bizwire) – A new global coalition, the RSV Alliance, has been launched to raise awareness about the risks of respiratory syncytial virus (RSV) infections, with a focus on aging populations and individuals with underlying health conditions. With core members including leading advocacy organizations the International Federation on Ageing (IFA) [...]

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer 64% overall response rate in gynecological cancers at doses ≥6.4mg/kg Responses observed at all doses evaluated at 3.2mg/kg and above demonstrating wide therapeutic index of Zymeworks’ novel antibody-drug [...]

UFC® and Smith+Nephew announce multi-year extension of partnership

UFC® and Smith+Nephew announce multi-year extension of partnership

Smith+Nephew to continue as UFC’s Preferred Sports Medicine Technology Partner Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, and UFC the world’s premier mixed martial arts organization, have announced a multi-year extension of their landmark worldwide marketing partnership forged in 2024.  Under the renewal, Smith+Nephew will continue as UFC’s Preferred Sports Medicine Technology Partner, a [...]

DataVault AI and Wellgistics Health Announce Plans for PharmacyChain™ to Implement Manufacturer-to-Patient Blockchain-enabled Smart Contracts for the Prescription Drug Industry to Improve Efficiency and Patient Outcomes

DataVault AI and Wellgistics Health Announce Plans for PharmacyChain™ to Implement Manufacturer-to-Patient Blockchain-enabled Smart Contracts for the Prescription Drug Industry to Improve Efficiency and Patient Outcomes

Strategic Alliance Targets Digital Transformation of the $634.32 Billion (1) U.S. Prescription Drug Market Through Blockchain-Enabled Data Monetization and AI-Driven Efficiency Gains BEAVERTON, Ore., Oct. 22, 2025 (Korea Bizwire) – via IBN – DataVault AI, Inc. (“DataVault”) (NASDAQ: DVLT), leading the way in AI data experience, valuation, and monetization, and Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ: WGRX), a leader in [...]

Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year

Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year

ALBANY, N.Y., Oct. 21, 2025 (Korea Bizwire) – Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced its Burlington, MA sterile drug product facility has been named “Manufacturer of the Year” by the Massachusetts Legislative Manufacturing Caucus. The award was presented at the 10th Annual Manufacturing Awards Ceremony, held on [...]

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing authorization in September 2024 Partnership brings together both companies’ expertise in biosimilars TEL AVIV, Israel, Oct. 20, 2025 (Korea Bizwire) – Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries [...]

KFSHRC Performs World’s First Robotic Intracranial Tumor Resection … A New Era in Neurosurgery

KFSHRC Performs World’s First Robotic Intracranial Tumor Resection … A New Era in Neurosurgery

RIYADH, Saudi Arabia, Oct. 20, 2025 (Korea Bizwire) – In a historic leap for robotic medicine, King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed the world’s first robotic intracranial tumor resection, a groundbreaking achievement that sets a new global standard in neurosurgical precision and recovery. The surgery was conducted on [...]

Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC

Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC

Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were presented for the first time at ESMO 2025.  Confirmed response by blinded independent central review was 77%, with 96% of patients achieving disease control.1  Zongertinib recently received Breakthrough Therapy Designations for first-line treatment by the [...]

Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

SHANGHAI, Oct. 16, 2025 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the investigational new drug (“IND”) application for an open-label, two-arm, randomized, active-controlled, phase 2/3 clinical study comparing the company’s product, [...]

Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio

Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio

Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year. New, potentially best-in-class ADC is targeting a tumor selective marker present in a broad spectrum of cancers with high medical need. Ingelheim, Germany, and Seoul, Korea, 15 October 2025 – Boehringer Ingelheim and AimedBio, [...]